CHERYL WALKER to Carcinoma, Medullary
This is a "connection" page, showing publications CHERYL WALKER has written about Carcinoma, Medullary.
Connection Strength
1.615
-
A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2044-2049.
Score: 0.541
-
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence. Nat Commun. 2025 Nov 25; 16(1):10474.
Score: 0.232
-
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. Clin Cancer Res. 2025 Mar 17; 31(6):1057-1068.
Score: 0.221
-
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med. 2023 05; 13(5):e1267.
Score: 0.194
-
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.
Score: 0.158
-
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6.
Score: 0.141
-
Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 07; 13(7):414-421.
Score: 0.129